- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | SKB BIO (06990): 2026 INTERIM REPORT | 2 | HKEx | ||
| 14.09. | Kelun-Biotech: Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO | 285 | PR Newswire | CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational... ► Artikel lesen | |
| 09.09. | HSBC Research: Healthcare Sector Supported by Resilient Demand, Favors INNOVENT BIO, SKB BIO, WUXI APPTEC | 12 | AASTOCKS | ||
| 09.09. | HBM HOLDINGS-B and SKB BIO: HBM9378/WIN378 Asthma Treatment Launches Phase III Study | 1 | AASTOCKS | ||
| 08.09. | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT POSITIVE PHASE 2 INTERIM RESULTS AND INITIATION OF PHASE 3 STUDY OF SKB378/WIN378 IN ASTHMA | - | HKEx | ||
| 08.09. | Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study | 177 | PR Newswire | The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis... ► Artikel lesen | |
| SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 27.08. | Cancer Drug Sales Power Up Kelun-Biotech's Profit Engine | 2 | Benzinga.com | ||
| 27.08. | Sichuan Kelun Pharmaceutical Co., Ltd. H1 Income Rises | 1 | RTTNews | ||
| 17.08. | Kelun-Biotech H1 2026 presentation: commercialization revenue surges 112% | 2 | Investing.com | ||
| 17.08. | Kelun-Biotech Announces 2026 Interim Results | 362 | PR Newswire | CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated... ► Artikel lesen | |
| 17.08. | SKB BIO (06990): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 05.08. | SKB BIO (06990): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| 04.08. | SKB BIO (06990): DISCLOSEABLE TRANSACTION SUBSCRIPTION FOR WEALTH MANAGEMENT PRODUCT | - | HKEx | ||
| 30.07. | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT NEW INDICATION APPLICATION FOR CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (SAC-TMT) ACCEPTED BY THE NATIONAL ... | - | HKEx | ||
| 27.07. | Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565 | 292 | PR Newswire | CHENGDU, China, July 27, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that... ► Artikel lesen | |
| 27.07. | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB565 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 4 | HKEx | ||
| 16.07. | Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy | 1 | Pharmaceutical Technology | ||
| 15.07. | Kelun scores sac-TMT win in first-line NSCLC population missing from Merck's massive phase 3 program | 4 | FiercePharma | ||
| 15.07. | Kelun Biotech, Harbour BioMed Get China Approval For IND Application Of Asthma Drug; Shares Up | 2 | RTTNews | ||
| 15.07. | Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint | 620 | PR Newswire | As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06... ► Artikel lesen |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,405 | +5,80 % | EQS-News: CPT GmbH: Warren Wise entschlüsselt Qiagens DNA | EQS-News: CPT GmbH
/ Schlagwort(e): Research Update/Jahresbericht
Warren Wise entschlüsselt Qiagens DNA
25.09.2026 / 18:15 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| CG ONCOLOGY | 67,38 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,640 | 0,00 % | Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days | ||
| TARSUS PHARMACEUTICALS | 73,00 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting | ||
| PRAXIS PRECISION MEDICINES | 295,78 | +0,09 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| VERA THERAPEUTICS | 30,420 | 0,00 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,755 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,225 | -0,06 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 10,500 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen | |
| MBX BIOSCIENCES | 58,51 | 0,00 % | Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential | ||
| EDGEWISE THERAPEUTICS | 41,400 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,790 | 0,00 % | Stifel reiterates Amylyx stock rating on avexitide confidence | ||
| KYMERA THERAPEUTICS | 107,37 | -0,02 % | B.Riley reiterates Kymera Therapeutics stock rating on new trial data | ||
| ADARX PHARMACEUTICALS | 18,250 | 0,00 % | HBM Healthcare Investments AG: HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,125 | +0,12 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen |
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.